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Strengths and limitations of the study
 ► The use of the Slovenian national multicentric reg-
istry biorx.si which prospectively collects safety and 
effectiveness data from up to 95% of rheumatoid ar-
thritis (RA) and ankylosing spondylitis (AS), and up to 
80% of psoriatic arthritis (PsA) patients treated with 
targeted disease- modifying antirheumatic drugs 
(DMARDs), including all commercially available tu-
mour necrosis factor inhibitors since 2008.
 ► The availability of detailed results of the mandatory 
national latent tuberculosis (TB) infection screening 
and TB chemoprophylaxis.
 ► The cross- link of biorx.si and the mandatory 
National Tuberculosis Registry that contains data on 
all TB cases in Slovenia enabled us to identify and 
describe all TB cases in detail.
 ► The biorx.si lacks a comparator cohort of targeted 
DMARD- naïve patients.
 ► The low count of cases in our cohort precluded the 
exploration of potential predictors of TB.
AbStrACt
Objectives This study aimed to assess the risk of 
tuberculosis (TB) in patients with rheumatoid arthritis (RA), 
ankylosing spondylitis (AS) and psoriatic arthritis (PsA) 
treated with any of the commercially available tumour 
necrosis factor inhibitors (TNFis) in Slovenia.
Design This is a cohort, registry ( biorx. si) cross- linked 
with the Slovenian National TB Registry.
Setting National, involving all Slovenian rheumatology 
centres (six secondary and two secondary/tertiary).
Participants 2429 patients with RA, AS or PsA exposed to 
at least one TNFi participated in the study.
Primary and secondary outcome measures The 
primary outcome measures were age- adjusted and sex- 
adjusted TB incidence rates (IRs) and the standardised 
incidence ratios (SIRs) compared with the general 
population exploring different TNFi exposure windows. 
The secondary outcome measures were a detailed 
characterisation of the national latent tuberculosis 
infection (LTBI) screening and TB chemoprophylaxis 
protocol implementation.
results Among the 2429 patients exposed to at least one 
TNFi for a total of 10 445 (49% RA, 33% AS and 18% PsA) 
person- years (PY), 99% completed LTBI screening and 6% 
required TB chemoprophylaxis. Six RA (three adalimumab, 
three certolizumab), two PsA (two golimumab) and zero 
AS patients developed TB. Five out of eight had miliary TB, 
three out of eight had pulmonary TB and two patients died. 
The age- standardised and sex- standardised TB IR (95% 
CI) per 100 000 PYs/SIRs (95% CI) compared with the 
general Slovenian population for the current TNFi exposure 
were 52 (0 to 110)/6.7 (0.6 to 80), 47 (0 to 110)/6.1 (0.3 to 
105), 45 (0 to 109)/5.8 (0.3 to 112) overall, in RA and PsA, 
respectively.
Conclusions The TB IR in the Slovenian patients with RA, 
AS and PsA treated with TNFi was comparable with TB IRs 
in TB non- endemic countries with less than a tenth of the 
patients requiring TB chemoprophylaxis.
IntrODuCtIOn
Tumour necrosis factor inhibitors (TNFis), 
commonly used to treat rheumatoid arthritis 
(RA), ankylosing spondylitis (AS) and 
psoriatic arthritis (PsA), have been impli-
cated in increasing the risk of tuberculosis 
(TB), especially in patients with a pre- existing 
latent tuberculosis infection (LTBI) in both 
the real- world setting and the randomised 
controlled trials (RCTs).1 2 This risk can be 
mitigated, but not avoided, by screening the 
patients for LTBI and initiating TB chemo-
prophylaxis when needed before starting a 
TNFi.3
A recent meta- analysis of RCTs in various 
diseases has shown that TNFi doubled the 
chance of TB.2 The short duration of the 
RCTs may lead to an underestimation of TB 
incidence rates (IRs), hence most data on the 
subject have come from the real- world obser-
vational studies and open label extensions 
(OLEs) of the RCTs. After the recognition 
of the importance of LTBI screening and TB 
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chemoprophylaxis, the TB IRs vary from 15 to 780 per 
100 000 person- years (PY), which is 12–35 times higher 
than in the respective general populations and 2–29 times 
higher than in the respective targeted disease- modifying 
antirheumatic drug (tDMARD)- naïve patients.4–12 Most 
of the data come from RA cohorts, mostly on infliximab, 
adalimumab and etanercept. The data on golimumab 
and certolizumab are scarce. The TB IR observed in RCTs 
and OLEs per 100 000 PY of golimumab overall for RA, AS 
and PsA, and of certolizumab for RA were 230 (95% CI 
140 to 350) and 470 (95% CI 340 to 640), respectively13 14 
(table 1). Other factors that may influence TB IR make 
the generalisability of the results difficult. It is appreci-
ated that the TB IR is higher in TB endemic areas, but 
also in tDMARD- naïve RA patients, and when TNFis are 
combined with conventional synthetic disease- modifying 
antirheumatic drugs (csDMARDs).15
Most of the above- mentioned studies were unable 
to ascertain the details of the implementation of LTBI 
screening protocols and TB chemoprophylaxis. The LTBI 
screening protocol and chemoprophylaxis recommenda-
tions differ and may impact TB IR. Common screening 
protocols include the TB exposure history, tuberculin 
skin test (TST) or interferon-γ release assays (IGRA), and 
chest X- ray (CXR). In most countries, 9 months of isoni-
azid treatment is used for chemoprophylaxis.
With the availability of IGRA, for example, Quantiferon 
TB Gold in a tube (QTB), the much cheaper TST, has 
fallen out of favour due to difficulties with the availability 
of Bacillus Calmette–Guérin (BCG), because the patients 
have to return to the clinic for evaluation, problems with 
interpretation, especially in BCG- vaccinated populations, 
and due to its high sensitivity, which may lead to the over-
prescription of TB chemoprophylaxis. A recent meta- 
analysis of studies comparing the performance of TST 
versus IGRA found the methods comparably effective; 
however, the included studies were probably underpow-
ered to detect the differences.16 Another recent report 
also suggested that the combination TST was more cost- 
effective than QTB in screening for LTBI, at the expense 
of a 20% increase in TB chemoprophylaxis.17
The epidemiological impact of TNFi on the IR of TB 
in Slovenia has thus far not been studied. Our aim was 
to determine the IR of TB among patients with RA, AS 
and PsA treated with all commercially available TNFis 
(adalimumab, certolizumab, etanercept, golimumab and 
infliximab) following a uniform LTBI screening protocol 
relying mainly on TST and CXR, using the national  biorx. 
si registry in comparison with the general population.
MethODS
Setting
The  biorx. si, established in February 2008, is a manda-
tory, national registry used to prospectively collect demo-
graphic, effectiveness and safety data of patients treated 
for RA, AS or PsA with tDMARDs (online supplementary 
table 1).18 In Slovenia, tDMARDs are selected jointly by 
the patient and their attending rheumatologist and are 
fully reimbursed by the national health insurance. The 
patients are classified in accordance with the modi-
fied 1987 American College of Rheumatology (ACR) 
criteria, or European League Against Rheumatism 
(EULAR)/ACR 2010 criteria for RA, the modified 1984 
New York criteria for AS and the ClASsification for Psori-
atic ARthritis (CASPAR) criteria for PsA.19–22 The data 
are entered by the attending rheumatologists, the sole 
prescribers of tDMARDs, from the two secondary/tertiary 
and six secondary Slovenian rheumatology centres, every 
3 months during the first year of treatment, and every 6 
months thereafter if the patient is stable on the current 
therapy. We estimate an over 95% coverage of patients 
with RA and AS, and over 80% coverage of patients with 
PsA, because patients with PsA in whom the tDMARD 
was prescribed by a dermatologist for psoriasis are not 
included in the  biorx. si.
The National Tuberculosis Registry was established in 
1954. The reporting of the cases to the registry is oblig-
atory and thus 100% complete. From 2001, the registry 
also collects data on persons who were in close contact 
with patients with TB and patients screened for LTBI. All 
Slovenian newborns prior to 1 January 2005 were vacci-
nated with BCG. The National Tuberculosis Registry was 
the source of the data on the annual, and age- specific 
and sex- specific IRs of TB in the general population. 
The national annual TB IR in Slovenia steadily declined 
from 2007 to 2017 from 10.8 to 5.8 cases per 100 000, 
respectively.
Study population and tb case identification
We included all patients in the  biorx. si exposed to at least 
one TNFi adalimumab (available since 2004), certoli-
zumab (2010), etanercept (2004), golimumab (2010) or 
infliximab (2000) up to 30 November 2018. We identified 
cases of TB by exploring the spontaneous adverse event 
reports in the  biorx. si, and, to avoid missing any cases 
of TB, we cross- matched our records with the manda-
tory National Tuberculosis Registry. We considered two 
windows of exposure to identify cases: in the first analysis, 
we attributed TB to the most recent TNFi used before the 
diagnosis of TB, regardless of the interval between the 
last TNFi dose and the diagnosis of TB, and in the second 
analysis, we only considered patients with TB as cases if 
TB was diagnosed within a 90- day period after the last 
administered dose (current TNFi use).
exposure to tnFis
We calculated the exposure time expressed in PY for 
each individual TNFi. The beginning of exposure was the 
date of the first administration. The end of exposure was 
determined as (1) the date of the last dose of the TNFi 
plus a 90- day washout period in patients who discon-
tinued therapy, even for patients who were switched to 
another tDMARD during the washout period, or (2) the 
date of the last recorded visit plus 180 days for patients 
during the first year of follow- up, or plus 270 days for 
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the patients who were followed up for more than 1 year. 
The added exposure time was censored on 30 November 
2018. The added time windows reflect the usual  biorx. si 
entry pattern as described above and the washout period 
used in previous studies.
Latent tb screening protocol
The LTBI screening protocol prior to the initiation of any 
tDMARDs has been mandatory in Slovenia since 2003. It 
consists of two steps. In the first step, the rheumatologist 
considers the TB exposure history, TST and CXR report. 
If there is a low risk of TB exposure, the TST is <5 mm 
and the CXR report is within normal limits, the rheuma-
tologist prescribes a tDMARD without further testing. If 
there is a history of a high risk of TB exposure, a TST≥5 
mm or a CXR report suggests changes consistent with the 
active or past TB, we refer the patient to a pulmonologist 
for further evaluation. The pulmonologist always orders 
IGRA, cultures of induced sputum or other samples, and 
sometimes additional tests such as chest CT. Finally, the 
pulmonologist approves tDMARD based on the addi-
tional testing or prescribes and manages TB chemopro-
phylaxis prior to tDMARD initiation. A 3- month course of 
rifampin and isoniazid is the standard chemoprophylaxis 
regimen used in Slovenia. The details of this screening 
protocol, except for the history of TB exposure, are 
recorded in  biorx. si.
Statistical analysis
Appropriate descriptive statistics were used to describe 
the cohort. No imputation of missing data was performed. 
We estimated the crude, and age- standardised and 
sex- standardised TB IR among subgroups of patients 
exposed to TNFi assuming the Poisson distribution. 
Direct method, with Slovenian population’s age and sex 
distribution, and age- specific and sex- specific IRs of TB 
between 2007 and 2017 divided into 5- year age brackets 
as the standard population (sources: Statistical Office 
of Slovenia, National Tuberculosis Registry) was used to 
estimate the age- standardised and sex- standardised TB 
IR and TB SIR. Data preparation and statistical analyses 
were done in the R V.3.5.2 (R Foundation for Statistical 
Computing, Vienna, Austria).
Patient consent
All patients gave a written informed consent to the use of 
data from  biorx. si for research purposes.
Patient and public involvement
Patients and the public were not involved in study 




During period under study, 2636 patients were enrolled 
into  biorx. si. Of these, 2429 (92%) were treated with at 
least one TNFi and they represented our study population. 
There were 1355 (55.8%) patients with RA, 661 (27.2%) 
with AS and 413 (17.0%) with PsA. The baseline charac-
teristics of the cohort are presented in table 2.
results of latent tb screening
The first screening step, comprising TST and CXR, 
was completed and recorded in the  biorx. si for 98.9% 
of patients. In 77% of patients, this was the only step 
performed, as both TST and CXR were not suggestive 
of LTBI. The second screening step, that is, referral to a 
pulmonologist for further evaluation, was done in 23% 
of patients. An IGRA test was done in 466 (19.1%) and 
was positive in 143/466 (30.7%) of the tested patients. 
LTBI chemoprophylaxis prior to the TNFi treatment was 
prescribed by pneumologists to 146 (6.0%) patients. The 
details of the screening protocol outcomes are presented 
in figure 1.
tb cases
The reports of TB cases in patients with RA, AS and PsA 
in  biorx. si matched the cases recorded in the National 
Tuberculosis Registry. There were no cases of TB 
recorded in the National Tuberculosis Registry among 
patients with RA, AS and PsA exposed to TNFi before the 
biorx. si was established. An additional case of TB after 
exposure to a TNFi was identified in the National Tuber-
culosis Registry in a patient with a predominantly periph-
eral spondylarthritis who did not fulfil the enrolment 
criteria for  biorx. si. There were eight cases of TB (six out 
of eight female) in patients ever exposed to a TNFi. Six 
out of eight patients had RA, two out of eight had PsA and 
none had AS. All cases were confirmed using a culture, 
and all isolated strains of Mycobacterium tuberculosis were 
susceptible to rifampicin and isoniazid. Five out of eight 
patients had extrapulmonary TB and five out of eight had 
miliary TB. Two patients with miliary TB died. The time 
from the first dose of TNFi to the diagnosis of TB ranged 
from 74 to 724 days. Four out of eight patients were only 
screened using TST and CXR, the remaining had had the 
IGRA done, and were also examined by a pulmonologist. 
One out of eight patients received a 3- month chemopro-
phylaxis with rifampin and isoniazid prior to the TNFi 
therapy. Seven out of eight patients developed TB after 
being exposed to only one TNFi, and one out of eight 
after three TNFis (adalimumab, infliximab and finally 
golimumab). One patient developed TB a year after 
stopping adalimumab, and another a year and a month 
after stopping adalimumab, having passed a second LTBI 
screening that included TST, CXR, IGRA and a pulmo-
nologist, and had been treated with the first two doses 
of rituximab a month prior to developing TB. Six out of 
eight patients were exposed to glucocorticoids at the time 
of developing TB, and seven out of eight were exposed to 
csDMARDs (four out of seven methotrexate, three out of 
seven leflunomide). None of incident cases were exposed 
to tDMARDs with other modes of action prior to devel-
oping TB. The details of individual cases are presented 
in table 3.
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N 2429 1355 661 413
TNFi exposure, person- years (% of all) 10 455 5175 (49) 3431 (33) 1849 (18)
  Adalimumab 4140 (39) 1891 (37) 1393 (41) 856 (46)
  Certolizumab 771 (7) 686 (13) 41 0 (1) 44 0 (2)
  Etanercept 3002 (29) 1779 (34) 794 (23) 429 (23)
  Golimumab 1217 (12) 375 0 (7) 555 (16) 287 (16)
  Infliximab 1325 (13) 444 0 (9) 648 (19) 233 (13)
Exposure, years, median (IQR) 2.3 (0.8–5.7) 1.8 (0.7–4.8) 2.8 (0.9–6.0) 2.0 (0.9–4.9)
% female 63.0 81.2 36.2 46.2
Age at diagnosis, years, median (IQR) 44.1 (34.6–52.9) 49.0 (39.5–56.1) 36.8 (29.0–46.3) 40.4 (33.2–49.0)
Age at first bDMARD, years, median (IQR) 53.1 (44.0–61.0) 56.7 (48.8–64.2) 45.6 (35.7–54.8) 49.4 (41.9–56.1)
Time to first bDMARD, years, median (IQR) 5.8 (2.2–12.5) 5.8 (2.4–12.3) 3.9 (1.0–11.1) 4.8 (1.6–11.5)
% RF positive 78
% ACPA positive 76
% HLA B27 positive 79 23
% ever smokers 29 29 37 28
History of comorbidities
  % diabetes 7 7 8 6
  % COPD 2 3 1 0
  % asthma 4 5 3 4
  % cancer 2 3 1 2
Prior csDMARDs, median (IQR) 3 (2–4) 0 (0–1) 3 (2–3)
  % on csDMARD 61 78 14 68
  % on methotrexate 52 66 11 53
  % on leflunomide 10 14 0 15
  % on sulfasalazine 3 2 3 5
  % on glucocorticoids 25 39 3 7
Baseline CRP, mg/L, median (IQR) 11 (4.1–25) 11 (5.0–25) 9 (2.1–23) 8 (3.0–17)
Baseline ESR, median (IQR) 31 (17–48) 36 (21–52) 22 (11–39) 24 (12–38)
Baseline DAS28, mean (SD) 6.12 (1.09) 5.11 (1.28)
Baseline SDAI, mean (SD) 37.86 (13.24) 28.27 (12.5)
Baseline CDAI, mean (SD) 35.86 (12.65) 26.83 (12.38)
Baseline BASDAI, mean (SD) 6.8 (1.7)
Baseline BASFI, mean (SD) 5.6 (2.4)
Baseline ASDAS- CRP, mean (SD) 3.75 (0.89)
Baseline PromisHAQ, 0–100, mean (SD) 38.48 (24.2) 43.1 (24.1) 34.0 (21.1) 35.14 (22.1)
BASDAI, Bath Ankylosing Spondylitis Activity Index; CDAI, Clinical Disease Activity Index; COPD, chronic obstructive pulmonary disease; CRP, 
C reactive protein; DAS28, Disease Activity Score based on a 28- joint count; ESR, erythrocyte sedimentation rate (mm in the first hour); n/a, not 
applicable; SDAI, Simplified Disease Activity Index.
tb Irs per 100 000 patient-years
The crude TB IRs and age- standardised and sex- 
standardised TB IRs, and SIRs for the two considered 
TB case definitions for the entire cohort and stratified 
by indication and TNFi are presented in table 4. There 
were no TB cases among patients with AS and no cases 
among etanercept and infliximab users regardless of 
indication.
DISCuSSIOn
In the present study, we report the TB IR in a well- 
defined prospective cohort of patients with RA, AS and 
PsA exposed to any of the five commercially available 
TNFis in Slovenia, a country with a low TB incidence 
in the general population, who underwent a unified 
mandatory LTBI screening and the TB chemoprophy-
laxis protocol.
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Figure 1 Detailed screening outcomes and latent tuberculosis chemoprophylaxis in patients with rheumatoid arthritis, 
ankylosing spondylitis and psoriatic arthritis ever exposed to TNFis. CP, chemoprophylaxis; CXR, chest X- ray; LTBI, latent 
tuberculosis infection; TNFi, tumour necrosis factor-α inhibitor; TB, tuberculosis; TST, tuberculin skin test.
Not unexpectedly, the overall age- standardised and 
sex- standardised TB IR in patients exposed to TNFi was 
higher than in the general Slovenian population (SIR 
7–9), but comparable with reports from other non- 
endemic countries (table 1). This was achieved without 
delaying the initiation of TNFi in over three- quarters of 
patients based on negative TST and CXR, a short delay in 
less than a fifth of patients who underwent pulmonolog-
ical testing and an approximately 3- month delay in 6% of 
patients who were prescribed TB chemoprophylaxis with 
rifampin and isoniazid. This chemoprophylaxis rate was 
much lower than in France, where the incidence of TB 
and population BCG vaccination exposure are similar to 
Slovenia, and where they have shown that replacing TST 
with an IGRA halved the share of patients requiring TB 
chemoprophylaxis prior to the initiation of TNFi from 
45.7% to 27.3%, respectively.23 Unfortunately, but not 
unexpectedly, the mandatory screening did not prevent 
TB infections altogether (table 3).3 Even one patient who 
successfully completed TB chemoprophylaxis developed 
TB, which, we suspect, may have been due to patient’s 
suboptimal adherence to TB chemoprophylaxis or newly 
acquired TB infection. Comparable with previous reports, 
a substantial proportion of the patients had extrapulmo-
nary and disseminated TB.4 In four out of eight cases the 
screening was completed after TST and CXR alone, and 
we wondered if performing an IGRA could help prevent 
those cases. However, TST, especially in patients vacci-
nated with BCG, was shown to be more sensitive than 
IGRA for the detection of LTBI and should not have led 
to an underprescription of chemoprophylaxis.17 23 We 
are further reassured that our ‘two- step’ LTBI screening 
strategy works well in our setting, by using the recent 
French cost- effectiveness analysis that compared eight 
IGRA- based LTBI screening regimens, which has shown 
that performing Quantiferon TB Gold only in patients 
who were TST positive resulted in the most cost- effective 
LTBI screening regimen and suggested that the French 
national screening recommendations could be changed 
on reflection.24 It is clear that the TB IR is higher in TB 
endemic environments,2 and while there is a low inci-
dence of TB in the general Slovenian population, Slovenia 
is a small country neighbouring TB endemic countries. 
Slovenians thus do not even have to travel far to get in 
contact with active TB and potentially acquire TB, which 
we believe happened to at least one patient in our cohort. 
A new TB infection rather than the reactivation of LTBI 
is also suggested by the much longer than expected time 
from the TNFi treatment onset to the development of 
TB in seven out of eight patients in our cohort.4 Having 
said that, it may be prudent to consider introduction of 
systematic TB surveillance and re- screening in patients 
with an increased risk for TB infection.25 26
There were no cases of TB among patients with AS. 
Although this may be due to chance, these patients were 
on average younger, and thus had fewer comorbidities, 
a lower inflammatory burden of disease and had been 
less often exposed to csDMARDs and glucocorticoids 
compared with patients with RA. This was not unexpected, 
as it has been shown that different inflammatory diseases 
may have different risks for TB infections, for example, it 
has been shown that tDMARD- naïve RA patients have an 
increased TB IR in comparison with the general popula-
tion,9 while those with spondyloarthritides do not.10
There were no cases of TB among patients treated 
with infliximab and etanercept. For infliximab, the first 
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available TNFi, this may be due to the low exposure, 
owing to its route of administration. Between 2010 and 
2013, we recorded three cases of TB in patients with 
RA treated with certolizumab, which made us wonder 
whether this drug might not increase the risk of TB more 
than other TNFis. However, although the TB IRs were 
higher for certolizmab compared with other TNFi, the 
overlapping CIs suggest the differences are not signifi-
cant. The data on golimumab from our cohort are also 
difficult to interpret as both TB cases occurred in patients 
with PsA, where exposure to golimumab was short, and 
one of the cases occurred in a patient who was previously 
exposed to two other TNFis. There are few reports on 
the TB IR in patients exposed to certolizumab and goli-
mumab, which did not show any unexpected increases in 
risk for TB IR.13 14
We are aware that the results from various published 
studies are difficult to compare, because the studies were 
done in different patient populations, on endemic and 
non- endemic locations, at different time periods, patients 
were exposed to different tDMARDs, with different LTBI 
screening and TB chemoprophylaxis protocols. Due 
to the relative rarity of the events, the populations with 
different rheumatic diseases, or even other inflammatory 
diseases (eg, inflammatory bowel disease and psoriasis) 
were often pooled even when we know, that therapy is 
only a part of the patients’ risk of TB infection. Few studies 
deal with other comorbidities that could contribute to the 
risk of TB, because few registries capture this information 
in detail. These observations are reflected in our results. 
Another limitation of our study was the lack of a compar-
ator cohort of tDMARD- naïve patients. The low count 
of cases in our cohort also precluded the exploration of 
potential predictors of TB.
The strongpoints of our study were the detailed LTBI 
screening data, lacking in many similar studies, the use of 
the national registries  biorx. si and the National Tubercu-
losis Registry to identify and describe TB cases in detail, 
and exposure to all commercially available TNFi.
At 52 (95% CI 0 to 110) TB cases per 100 000 PY, the 
TB IR in the Slovenian patients with RA, AS and PsA 
treated with TNFi was comparable with TB IRs in TB non- 
endemic countries with less than a tenth of the patients 
exposed to TB chemoprophylaxis.
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